Adult cell therapy for brain neuronal damages and the role of tissue engineering

Gaëtan J R Delcroix, Paul C Schiller, Jean Pierre Benoit, Claudia N. Montero-Menei

Research output: Contribution to journalArticle

121 Citations (Scopus)

Abstract

No long term effective treatments are currently available for brain neurological disorders such as stroke/cerebral ischemia, traumatic brain injury and neurodegenerative disorders. Cell therapy is a promising strategy, although alternatives to embryonic/foetal cells are required to overcome ethical, tissue availability and graft rejection concerns. Adult cells may be easily isolated from the patient body, therefore permitting autologous grafts to be performed. Here, we describe the use of adult neural stem cells, adrenal chromaffin cells and retinal pigment epithelium cells for brain therapy, with a special emphasis on mesenchymal stromal cells. However, major problems like cell survival, control of differentiation and engraftment remain and may be overcome using a tissue engineering strategy, which provides a 3D support to grafted cells improving their survival. New developments, such as the biomimetic approach which combines the use of scaffolds with extracellular matrix molecules, may improve the control of cell proliferation, survival, migration, differentiation and engraftment in vivo. Therefore, we later discuss scaffold properties required for brain cell therapy as well as new tissue engineering advances that may be implemented in combination with adult cells for brain therapy. Finally, we describe an approach developed in our laboratory to repair/protect lesioned tissues: the pharmacologically active microcarriers.

Original languageEnglish
Pages (from-to)2105-2120
Number of pages16
JournalBiomaterials
Volume31
Issue number8
DOIs
StatePublished - Mar 1 2010

Fingerprint

Tissue Engineering
Cell- and Tissue-Based Therapy
Tissue engineering
Brain
Brain Diseases
Scaffolds (biology)
Cell Survival
Grafts
Transplants
Biomimetics
Chromaffin Cells
Adult Stem Cells
Neural Stem Cells
Retinal Pigment Epithelium
Tissue
Graft Rejection
Nervous System Diseases
Brain Ischemia
Mesenchymal Stromal Cells
Retinal Pigments

Keywords

  • Adult cells
  • Biomimetic surface
  • Brain disorders
  • Mesenchymal stromal cells
  • Pharmacologically active microcarriers
  • Scaffolds

ASJC Scopus subject areas

  • Biomaterials
  • Bioengineering
  • Ceramics and Composites
  • Mechanics of Materials
  • Biophysics

Cite this

Adult cell therapy for brain neuronal damages and the role of tissue engineering. / Delcroix, Gaëtan J R; Schiller, Paul C; Benoit, Jean Pierre; Montero-Menei, Claudia N.

In: Biomaterials, Vol. 31, No. 8, 01.03.2010, p. 2105-2120.

Research output: Contribution to journalArticle

Delcroix, Gaëtan J R ; Schiller, Paul C ; Benoit, Jean Pierre ; Montero-Menei, Claudia N. / Adult cell therapy for brain neuronal damages and the role of tissue engineering. In: Biomaterials. 2010 ; Vol. 31, No. 8. pp. 2105-2120.
@article{f37e0c26c9f04e4fa254c4311ee05064,
title = "Adult cell therapy for brain neuronal damages and the role of tissue engineering",
abstract = "No long term effective treatments are currently available for brain neurological disorders such as stroke/cerebral ischemia, traumatic brain injury and neurodegenerative disorders. Cell therapy is a promising strategy, although alternatives to embryonic/foetal cells are required to overcome ethical, tissue availability and graft rejection concerns. Adult cells may be easily isolated from the patient body, therefore permitting autologous grafts to be performed. Here, we describe the use of adult neural stem cells, adrenal chromaffin cells and retinal pigment epithelium cells for brain therapy, with a special emphasis on mesenchymal stromal cells. However, major problems like cell survival, control of differentiation and engraftment remain and may be overcome using a tissue engineering strategy, which provides a 3D support to grafted cells improving their survival. New developments, such as the biomimetic approach which combines the use of scaffolds with extracellular matrix molecules, may improve the control of cell proliferation, survival, migration, differentiation and engraftment in vivo. Therefore, we later discuss scaffold properties required for brain cell therapy as well as new tissue engineering advances that may be implemented in combination with adult cells for brain therapy. Finally, we describe an approach developed in our laboratory to repair/protect lesioned tissues: the pharmacologically active microcarriers.",
keywords = "Adult cells, Biomimetic surface, Brain disorders, Mesenchymal stromal cells, Pharmacologically active microcarriers, Scaffolds",
author = "Delcroix, {Ga{\"e}tan J R} and Schiller, {Paul C} and Benoit, {Jean Pierre} and Montero-Menei, {Claudia N.}",
year = "2010",
month = "3",
day = "1",
doi = "10.1016/j.biomaterials.2009.11.084",
language = "English",
volume = "31",
pages = "2105--2120",
journal = "Biomaterials",
issn = "0142-9612",
publisher = "Elsevier BV",
number = "8",

}

TY - JOUR

T1 - Adult cell therapy for brain neuronal damages and the role of tissue engineering

AU - Delcroix, Gaëtan J R

AU - Schiller, Paul C

AU - Benoit, Jean Pierre

AU - Montero-Menei, Claudia N.

PY - 2010/3/1

Y1 - 2010/3/1

N2 - No long term effective treatments are currently available for brain neurological disorders such as stroke/cerebral ischemia, traumatic brain injury and neurodegenerative disorders. Cell therapy is a promising strategy, although alternatives to embryonic/foetal cells are required to overcome ethical, tissue availability and graft rejection concerns. Adult cells may be easily isolated from the patient body, therefore permitting autologous grafts to be performed. Here, we describe the use of adult neural stem cells, adrenal chromaffin cells and retinal pigment epithelium cells for brain therapy, with a special emphasis on mesenchymal stromal cells. However, major problems like cell survival, control of differentiation and engraftment remain and may be overcome using a tissue engineering strategy, which provides a 3D support to grafted cells improving their survival. New developments, such as the biomimetic approach which combines the use of scaffolds with extracellular matrix molecules, may improve the control of cell proliferation, survival, migration, differentiation and engraftment in vivo. Therefore, we later discuss scaffold properties required for brain cell therapy as well as new tissue engineering advances that may be implemented in combination with adult cells for brain therapy. Finally, we describe an approach developed in our laboratory to repair/protect lesioned tissues: the pharmacologically active microcarriers.

AB - No long term effective treatments are currently available for brain neurological disorders such as stroke/cerebral ischemia, traumatic brain injury and neurodegenerative disorders. Cell therapy is a promising strategy, although alternatives to embryonic/foetal cells are required to overcome ethical, tissue availability and graft rejection concerns. Adult cells may be easily isolated from the patient body, therefore permitting autologous grafts to be performed. Here, we describe the use of adult neural stem cells, adrenal chromaffin cells and retinal pigment epithelium cells for brain therapy, with a special emphasis on mesenchymal stromal cells. However, major problems like cell survival, control of differentiation and engraftment remain and may be overcome using a tissue engineering strategy, which provides a 3D support to grafted cells improving their survival. New developments, such as the biomimetic approach which combines the use of scaffolds with extracellular matrix molecules, may improve the control of cell proliferation, survival, migration, differentiation and engraftment in vivo. Therefore, we later discuss scaffold properties required for brain cell therapy as well as new tissue engineering advances that may be implemented in combination with adult cells for brain therapy. Finally, we describe an approach developed in our laboratory to repair/protect lesioned tissues: the pharmacologically active microcarriers.

KW - Adult cells

KW - Biomimetic surface

KW - Brain disorders

KW - Mesenchymal stromal cells

KW - Pharmacologically active microcarriers

KW - Scaffolds

UR - http://www.scopus.com/inward/record.url?scp=74449086728&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74449086728&partnerID=8YFLogxK

U2 - 10.1016/j.biomaterials.2009.11.084

DO - 10.1016/j.biomaterials.2009.11.084

M3 - Article

C2 - 20005569

AN - SCOPUS:74449086728

VL - 31

SP - 2105

EP - 2120

JO - Biomaterials

JF - Biomaterials

SN - 0142-9612

IS - 8

ER -